Financials
Financial year 2025
Biotech Management & Consulting from Juprelle, company number BE0741644479, closed financial year 2025 with a result of € 109,454 after tax. For that financial year Biotech Management & Consulting recorded a gross margin of € 158,505 and equity of € 10,000. Compared with financial year 2024, the result moved from € 132,657 to € 109,454. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 1, 2026.
€ 10,000
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 109,454
▼ 17% vs 2024
Profit after tax over the fiscal year.
€ 78,500
▼ 52% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 109,454 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 15,416
▼ 47% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 11,133
▼ 50% vs 2024
€ 8,336 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.
€ 3,183
▲ 215% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 29,058
▼ 39% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 186,139 | € 183,370 | € 201,479 | € 158,505 | ▼ 21% |
| Profit after taxes | € 123,829 | € 119,960 | € 132,657 | € 109,454 | ▼ 17% |
| Equity | € 213,026 | € 109,457 | € 10,000 | € 10,000 | |
| Total debts | € 152,696 | € 224,450 | € 268,835 | € 137,789 | ▼ 49% |
| Cash | € 253,810 | € 225,895 | € 164,286 | € 78,500 | ▼ 52% |
| Retained profit | € 203,026 | € 99,457 | € 0 | € 0 | |
| Dividend | € 75,000 | € 223,529 | € 232,113 | € 109,454 | ▼ 53% |
| Bank debt | € 60,133 | € 41,219 | € 22,130 | € 11,133 | ▼ 50% |
| Balance sheet total | € 365,722 | € 333,907 | € 278,835 | € 147,789 | ▼ 47% |
Key figures of Biotech Management & Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Biotech Management & Consulting?
What happened at Biotech Management & Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 109,454 (▼ 17% vs 2024). Source: NBB ↗
- Edith Charlier became a director. NBB
- New establishment in Juprelle. KBO
- Hugues Wallemacq became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 123,829 profit in 2022 to € 109,454 profit in 2025.
Paid € 144,867 in corporate taxes since 2022.
Best year ever: 2024, with € 132,657 profit.
Paid out € 640,097 in dividends to the owners in total.
Management
Behind Biotech Management & Consulting are Edith Charlier and Hugues Wallemacq. Hugues Wallemacq is also behind EXO Biologics, IMCYSE, MAN & SCIENCE, BIOWIN and ExoXpert.
Directors
According to the 2025 annual accounts
Edith Charlier
Director
since 2024
since 2020
Establishments
Establishment units
Physical locations of this company
Rue Neuve 31
4458 Juprelle
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0741.644.479
- VAT number
- BE 0741.644.479
- Registered office
- Rue Neuve 31, 4458 Juprelle
- Names & denominations
- Biotech Management & Consulting
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 January 2020
- Peppol
- Active · Active since 7 Oct 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige vormen van onderwijs
Overige zakelijke dienstverlening, neg